TITLE:

EMA: CHMP adopted a positive opinion for Fasenra (benralizumab) 30-mg solution for injection in pre-filled syringes from AstraZeneca AB.

BRIEF:

EMA: CHMP adopted a positive opinion for Fasenra (benralizumab) 30-mg solution for injection in pre-filled syringes from AstraZeneca AB. Fasenra is intended as an add‑on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long‑acting beta‑agonists. (ATC code: R03DX10). The EC Decision will follow soon.